Sulfasalazine and mesalamine both treat ulcerative colitis, and sulfasalazine’s active metabolite is actually mesalamine itself, but sulfasalazine is FDA-approved specifically for ulcerative colitis, not Crohn’s disease, an important correction to a common misconception. This guide compares the two drugs, corrects the record on approved uses, and explains their relationship.
This is general information, not medical advice.
Sulfasalazine vs Mesalamine at a glance
| Sulfasalazine | Mesalamine | |
|---|---|---|
| FDA-approved for | Mild to moderate ulcerative colitis; remission maintenance | Ulcerative colitis (various formulations) |
| Crohn’s disease | Not FDA-approved; sometimes used off-label | Similarly not the primary FDA approval, off-label use varies by formulation |
| Contains sulfa component | Yes (sulfapyridine carrier) | No |
| Folic acid interaction | Yes, reduces absorption | Not a comparable interaction |
| Relationship | Splits into sulfapyridine + mesalamine (5-ASA) in the colon | Is the active anti-inflammatory component itself |
Important correction: sulfasalazine is not FDA-approved for Crohn’s disease
This is worth stating clearly, since it’s a common point of confusion. Sulfasalazine’s FDA-approved indications are specifically the treatment of mild to moderate ulcerative colitis, adjunctive therapy in severe ulcerative colitis, and prolonging the remission period between ulcerative colitis flares. According to a clinical reference source, sulfasalazine is FDA-approved for ulcerative colitis but not FDA-approved for Crohn’s disease, though it notes that randomized controlled trials have looked at sulfasalazine for Crohn’s disease, meaning off-label use does happen in practice based on some trial evidence, but it is not what the drug is officially approved to treat.
The relationship between the two drugs
Sulfasalazine is actually a combination molecule: it’s made of sulfapyridine (a sulfa antibiotic-related carrier molecule) linked to 5-aminosalicylic acid, which is mesalamine. When sulfasalazine reaches the colon, gut bacteria break this bond, releasing mesalamine to act locally on the inflamed colon tissue, while the sulfapyridine component is absorbed and eventually excreted. Clinical studies looking at rectal administration of the two components separately have indicated that the major therapeutic action of sulfasalazine may reside specifically in the mesalamine portion, not the sulfapyridine carrier.
This means mesalamine-only products essentially deliver the “active half” of sulfasalazine directly, without the sulfapyridine carrier, which is largely responsible for several of sulfasalazine’s more distinctive side effects.
Why the sulfa component matters
Because sulfasalazine contains a sulfa-related carrier molecule, it’s not an appropriate option for patients with a sulfa allergy, a real and important distinction from mesalamine, which does not carry this same sulfa-related risk. This is often one of the more clinically significant reasons a prescriber might choose mesalamine over sulfasalazine for a specific patient.
Side effects
Sulfasalazine’s most common associated adverse reactions in ulcerative colitis, occurring in about a third of patients, include anorexia, headache, nausea, vomiting, gastric distress, and reversible oligospermia (reduced sperm count, typically reversible after stopping the drug), a specific and clinically relevant consideration for men of reproductive age. More serious but less common reactions include hepatitis, pancreatitis, and blood cell count abnormalities, which is why complete blood counts and liver function tests are recommended before starting treatment and periodically during the first months of use.
Mesalamine’s side-effect profile is generally considered milder and doesn’t carry the sulfa-related risks, though it isn’t free of gastrointestinal side effects of its own, and rare kidney-related effects have been a subject of ongoing labeling attention across mesalamine and sulfasalazine products alike.
Who each might suit
Factors that may point toward mesalamine:
- A known or suspected sulfa allergy
- A preference to avoid sulfapyridine-related side effects specifically
- Fertility concerns in men, given sulfasalazine’s reversible effect on sperm count
Factors that may point toward sulfasalazine:
- Established good response and long-term tolerance already
- Cost considerations, since sulfasalazine has long been available generically
- A prescriber’s specific clinical reasoning based on disease severity and pattern
Frequently asked questions
Is sulfasalazine FDA-approved for Crohn’s disease?
No. Its FDA-approved indications are specifically for ulcerative colitis. It is sometimes used off-label for Crohn’s disease based on some trial evidence, but this is not its approved indication.
Is mesalamine part of sulfasalazine?
Yes. Sulfasalazine is metabolized in the colon into sulfapyridine and mesalamine (5-aminosalicylic acid); mesalamine is believed to be the primary active anti-inflammatory component.
Can someone with a sulfa allergy take sulfasalazine?
Generally, no, sulfasalazine contains a sulfa-related component (sulfapyridine) and isn’t appropriate for patients with a true sulfa allergy. Mesalamine does not carry this same concern.
Does sulfasalazine affect fertility?
It has been associated with reversible oligospermia (reduced sperm count) in men, generally reversible after stopping the medication, a consideration worth discussing with a doctor for men of reproductive age.
What monitoring is needed with sulfasalazine?
Complete blood counts (including differential white cell count) and liver function tests are recommended before starting and periodically, particularly during the first few months, given rare but serious blood and liver-related adverse reactions.